<DOC>
	<DOCNO>NCT00000892</DOCNO>
	<brief_summary>To compare proportion patient whose plasma HIV-1 RNA 500 copies/ml 16 week treatment . To assess safety , toxicity , tolerance treatment arm . While indinavir currently commonly prescribed protease inhibitor , optimal therapy person indinavir-containing regimen experience rebound viral load never experience decrease viral load 500 copy per milliliter unknown . Current clinical practice patient typically involve empiric use combination protease inhibitor ( saquinavir/nelfinavir saquinavir/ritonavir ) least 1 antiretroviral agent patient little prior exposure . This may involve use 1 reverse transcriptase inhibitor ( RTIs ) nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) . This study attempt formally evaluate option indinavir-experienced patient .</brief_summary>
	<brief_title>A Study Several Anti-HIV Drug Combinations HIV-Infected Patients Who Have Used Indinavir</brief_title>
	<detailed_description>While indinavir currently commonly prescribed protease inhibitor , optimal therapy person indinavir-containing regimen experience rebound viral load never experience decrease viral load 500 copy per milliliter unknown . Current clinical practice patient typically involve empiric use combination protease inhibitor ( saquinavir/nelfinavir saquinavir/ritonavir ) least 1 antiretroviral agent patient little prior exposure . This may involve use 1 reverse transcriptase inhibitor ( RTIs ) nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) . This study attempt formally evaluate option indinavir-experienced patient . Patients stratify HIV RNA ( 2,000 - 20,000 copies/ml versus 20,000 - 200,000 copies/ml ) , randomize 1 6 treatment arm follow : Arm A : Saquinavir ( SQV ) plus ritonavir ( RTV ) plus delavirdine ( DLV ) plus adefovir dipivoxil placebo . Arm B : SQV plus RTV plus DLV placebo plus adefovir dipivoxil . Arm C : SQV plus RTV plus DLV plus adefovir dipivoxil . Arm D : SQV plus nelfinavir ( NFV ) plus DLV plus adefovir dipivoxil placebo . Arm E : SQV plus NFV plus DLV placebo plus adefovir dipivoxil . Arm F : SQV plus NFV plus DLV plus adefovir dipivoxil . In addition assign study treatment patient receive L-carnitine supplement . Therapy administer 24 week . Patients average HIV RNA value Weeks 12 16 less 5,000 copy least 1 log baseline value may continue assign study treatment additional 24 week . [ AS PER AMENDMENT 3/30/98 : Subjects plasma HIV RNA great 5,000 copies/ml may elect continue discontinue study medication treatment extension seek best available treatment . ] [ AS PER AMENDMENT 06/11/98 : The dose adefovir dipivoxil reduce Week 16 . Alternatively , patient may discontinue adefovir dipivoxil/placebo substitute appropriate antiretroviral agent ( ) add appropriate antiretroviral agent ( ) reduced-dose regimen . Also , discretion protocol chairperson , patient study 16 week may substitute appropriate FDA-approved antiretroviral agent ( ) study medication must discontinue toxicity . Addition nonnucleoside reverse transcriptase inhibitor , protease inhibitor , investigational agent specifically exclude . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Chemoprophylaxis Pneumocystis carinii pneumonia patient CD4 cell count equal le 200 cells/mm3 . Allowed : Topical oral antifungal agent except ketoconazole itraconazole . Treatment , maintenance chemoprophylaxis approve agent opportunistic infection . Antibiotics . Systemic corticosteroids 21 day less acute problem . Recombinant erythropoietin ( rEPO ) granulocytecolony stimulate factor ( GCSF , filgrastim ) . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive ( sole form birth control ) , megestrol acetate , testosterone . Alternative therapy , vitamin , acupuncture , visualization technique . [ AS PER AMENDMENT 3/30/98 : Calcium channel blocker may use caution . ] Patients must : HIV1 infection document licensed ELISA confirm Western blot , HIV culture , HIV antigen , plasma HIV RNA , second antibody test ELISA . 2,000 200,000 HIV1 RNA copies/ml measure Rochecertified laboratory [ AS PER AMENDMENT 3/30/98 : use Roche Amplicor HIV1 Monitor ] within 30 day study entry . Signed , inform consent parent legal guardian patient le 18 year age . Prior Medication : Required : More 6 month cumulative indinavir therapy . Stable indinavircontaining antiretroviral regimen least 4 week [ 2 week AS PER AMENDMENT 3/30/98 ] prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Any active infection require acute treatment within 30 day [ 21 day AS PER AMENDMENT 3/30/98 ] prior study entry . Unexplained temperature great 38.5 degree 7 consecutive day within 30 day prior study entry . Malignancy , include Kaposi 's sarcoma , require systemic chemotherapy . Concurrent Medication : Excluded : Nonprotocolspecified immunomodulatory and/or antiretroviral agent . Systemic cytotoxic chemotherapy . Ketoconazole , itraconazole , rifampin , rifabutin , alprazolam , amiodarone , astemizole , bepridil , bupropion , cisapride , clorazepate , clozapine , diazepam , encainide , estazolam , flecainide , flurazepam , isotretinoin , meperidine , midazolam , piroxicam , propafenone , propoxyphene , quinidine , terfenadine , triazolam , zolpidem , phenytoin , phenobarbital , carbamazepine , ergot alkaloid [ AS PER AMENDMENT 3/30/98 : dexamethasone , ergot derivative , pimozide ] . Avoided : Herbal medication . Prior Medication : Excluded : At least 2 week total ritonavir and/or saquinavir ( hard gelatin capsule ) . NNRTIs ( nevirapine , delavirdine , DMP266 , etc . ) , saquinavir ( soft gelatin capsule ) , nelfinavir , 141W94VX478 , adefovir dipivoxil . Immunomodulator [ systemic immunomodulator AS PER AMENDMENT 3/30/98 ] investigational drug therapy within 30 day prior entry . Active immunization within 30 day [ 21 day AS PER AMENDMENT 3/30/98 ] prior entry .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>